Remedium Capital Partners, LLC — 13F Holdings & Portfolio
CIK 2104501 · latest 13F-HR filed 2026-08-07
Remedium Capital Partners, LLC manages $451.6M in 13F-reported U.S. long-equity assets across 6 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are ORKA (32.99%), SYRE (28.78%), APGE (17.24%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 1 new position, exited 1, added to 4, and trimmed 0.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
SUITE 800
WEST PALM BEACH, FL 33401
$451.6M
Long-equity book
6
Distinct positions
2026-06-30
Filed 2026-08-07
+1 / −1 / ↑4 / ↓0
vs 2026-03-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- Oruka Therapeutics Inc$72.2M +94.0%
- Spyre Therapeutics Inc$56.5M +77.0%
- Apogee Therapeutics Inc$28.8M +58.5%
- Jade Biosciences Inc$12.9M +58.1%
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | Oruka Therapeutics Inc | ORKA | 687604108 | $149.0M | 32.99% | 1,565,661 | SH |
| 2 | Spyre Therapeutics Inc | SYRE | 00773J202 | $130.0M | 28.78% | 1,464,169 | SH |
| 3 | Apogee Therapeutics Inc | APGE | 03770N101 | $77.9M | 17.24% | 586,691 | SH |
| 4 | Damora Therapeutics Inc | DMRA | 36322Q206 | $53.2M | 11.78% | 2,045,473 | SH |
| 5 | Jade Biosciences Inc | JBIO | 008064206 | $35.1M | 7.76% | 1,577,750 | SH |
| 6 | Crescent Biopharma Inc | CBIO | G2545C104 | $6.5M | 1.44% | 361,250 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-07 | $451.6M | 6 | 0002104501-26-000015 |
| 2026-03-31 | 2026-05-13 | $319.8M | 6 | 0002104501-26-000008 |
| 2026-03-31 | 2026-05-19 | $281.2M | 6 | 0002104501-26-000010 |
| 2025-12-31 | 2026-02-12 | $170.2K | 6 | 0002104501-26-000004 |